2,6-Diaminopurine Corrects UGA Nonsense Mutations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for nonsense mutations, such as those causing cystic fibrosis and muscular dystrophy, are limited by the toxicity and inefficiency of existing transreading activators like G418 and ataluren, which fail to effectively restore gene expression.
Innovation Solution
The use of 2,6-diaminopurine (DAP) as a therapeutic agent, potentially combined with other transreading activators, to selectively correct UGA nonsense mutations by promoting transreading and reducing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing transreading activators like G418 and ataluren are used to correct nonsense mutations, then transreading activity is achieved, but toxicity is significant and corrective efficiency is limited
Solution Approach 1:
The patent changes the chemical structure parameter by using 2,6-diaminopurine (DAP) instead of existing transreading activators like G418 and ataluren. This structural parameter change results in a molecule that maintains transreading activity while significantly reducing toxicity and improving corrective efficiency for nonsense mutations.
Solution Approach 2:
The patent creates a new transreading activator (DAP) that copies the essential functional property of inducing transreading from existing molecules like G418 and ataluren, but with improved safety and efficiency characteristics. DAP replicates the transreading induction mechanism while avoiding the toxic side effects of previous compounds.
2Productivity
If G418 is used as a transreading activator, then transreading efficiency is high, but therapeutic development is blocked due to toxicity
Solution Approach 1:
The patent changes the chemical identity parameter from G418 to 2,6-diaminopurine (DAP), maintaining the transreading induction capability while fundamentally altering the toxicity profile. This parameter substitution allows high transreading efficiency to be achieved without the therapeutic-development-blocking toxicity of G418.
3Reliability
If ataluren is used to treat nonsense mutations, then transreading is activated, but gene expression restoration is not effectively demonstrated
Solution Approach 1:
The patent substitutes ataluren with 2,6-diaminopurine (DAP) to improve the conversion of transreading activation into actual gene expression restoration. While ataluren activates transreading, the patent demonstrates that DAP more effectively restores gene expression, suggesting a parameter optimization in the transreading induction mechanism.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
DAP demonstrates a higher corrective activity than existing molecules, effectively restoring protein expression with minimal toxicity, thereby addressing the limitations of current treatments for nonsense mutation-related diseases.
Implementation Method 1
Read-through is a mechanism leading to the incorporation, during translation, of an amino acid when the ribosome reaches a premature stop codon. Transreading is not observed on the physiological stop codon... The transreading of a premature stop codon from an mRNA carrying this premature stop codon makes it possible to lead to the synthesis of a protein of identical size to that of the wild protein
Data Source
Figure 1A
Figure 1B
Figure 2A~2C
AI summary
The present invention relates to 2,6-diaminopurine (DAP) for use in the treatment of a disease caused by a nonsense mutation in a gene, leading to the premature insertion of a UGA stop codon.